Vibeke Strand | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Dvora Joseph Davey | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dvora Joseph Davey | Clinical Trials | Best Researcher Award 

Dr Dvora Joseph Davey, University of California, Los Angeles, UCLA, South Africa

Dr. Dvora Joseph Davey is a distinguished epidemiologist with a focus on infectious diseases, particularly HIV and STIs. Holding a Ph.D. in Epidemiology from UCLA, her research, mainly in sub-Saharan Africa, aims to reduce the burden of HIV through innovative interventions. As a Principal Investigator in clinical trials, Dr. Davey has contributed significantly to global HIV prevention efforts, especially for pregnant women. She is actively involved in policy-making with groups like the WHO and NIH, shaping global health initiatives. Her leadership, extensive research, and mentorship in global health make her an exemplary figure in public health. 🌍🔬💉

Publication Profile

google scholar

scopus

orcid

Education

Dr. Dvora Joseph Davey has an impressive academic background, beginning with a B.A. in International Affairs and French from the University of Colorado, Boulder, in 1998. She went on to earn a Master of Public Health (M.P.H.) in Population and Reproductive Health Sciences from Columbia University in 2003. Dr. Davey completed her Ph.D. in Epidemiology at the University of California, Los Angeles, in 2016, followed by a fellowship in Epidemiology of HIV at the University of North Carolina in 2017. She furthered her expertise with a postdoctoral fellowship in Global HIV Prevention at UCLA in 2018. 🌍📚

Scientific Appointments

Dr. Dvora Joseph Davey has held several prestigious positions throughout her career. Currently, she serves as an Associate Professor in Infectious Diseases and Epidemiology at UCLA’s School of Medicine and School of Public Health, respectively. She also holds honorary roles at the University of Cape Town and Desmond Tutu Health Foundation. Dr. Davey’s research includes being the Principal Investigator on a study about sexual behavior and PrEP acceptability. Her past positions include HIV Director at Population Services International in Mozambique and Director at the Rwanda-Emory HIV Research Group. With her diverse roles, Dr. Davey has had a significant global impact. 🌍🩺📊

Professional Memberships

Dr. Dvora Joseph Davey has made significant contributions to the field of HIV and reproductive health, serving as an Assistant Editor for renowned journals such as AIDS, JIAS, and PloS Global Health. She is also an active member of the South African Clinical Research Association and the American Public Health Association. Her honors include invitations to present at major conferences like HIVR4P 2024 in Peru and WHO Working Group meetings. Dr. Davey has co-chaired several influential research working groups, including on PrEP in pregnancy, and received multiple awards, including UCLA’s Epidemiology Department Summer Fellowship. 🌍📚🎤

Awards

Dr. Dvora Joseph Davey is a renowned researcher whose work focuses on HIV prevention and treatment, particularly in pregnant and breastfeeding women. Her studies address key challenges in high HIV incidence communities, especially in Sub-Saharan Africa. Dr. Davey investigates Pre-exposure Prophylaxis (PrEP) access, adherence, and effectiveness among pregnant women, emphasizing the need for female-controlled HIV prevention methods during vulnerable periods. Additionally, she explores the integration of STI testing, alcohol use, and the impact of intimate partner violence on HIV risk. Her contributions significantly influence HIV-related healthcare policies, aiming to reduce transmission and improve outcomes in these populations. 👩‍🔬🌍💉

Policy Involvement

Dr. Dvora Joseph Davey has made significant contributions to national and international HIV and STI policy-making. Her leadership in key working groups, including the National PrEP and Prevention of Vertical Transmission of HIV Working Groups, as well as the World Health Organization’s Working Group on Long-Acting PrEP in pregnancy, highlights her expertise and influence. These positions enable Dr. Davey to play a pivotal role in translating scientific research into actionable policies, ensuring her work impacts not only the scientific community but also global health policies. Her efforts amplify the reach of her research, making a lasting impact on public health worldwide. 🌍🩺💉

Leadership

Dr. Dvora Joseph Davey’s leadership in managing large-scale clinical trials and mentoring emerging public health and epidemiology professionals showcases her dedication to education and capacity-building in global public health. As a recipient of the prestigious NIH/Fogarty International Research Scientist Development Award (IRSDA) and the follow-on R01 award, Dr. Davey has solidified her position as a thought leader in the field. Her commitment to fostering continuous learning and improvement within the global health community reflects her deep influence and dedication to advancing public health practices worldwide. 🎓🌍💉👩‍🔬

Ongoing Projects

Dr. Dvora Joseph Davey’s ongoing research, supported by NIH and Gilead Corporation, plays a crucial role in addressing HIV within vulnerable populations. Her work on projects like PrEP-PP and SCOPE-PP, alongside innovative initiatives such as a community-based peer-led intervention to tackle alcohol use and HIV risk in pregnant women, highlights her proactive approach to solving complex public health challenges. Dr. Davey’s research aims to create effective, targeted solutions that address the unique needs of at-risk communities, contributing significantly to advancing HIV prevention and care efforts. 💡🧑‍🔬🩺🌍

Research Focus

Dr. Dvora Joseph Davey is a prominent researcher specializing in HIV prevention, sexually transmitted infections (STIs), and maternal health. Her work focuses on pre-exposure prophylaxis (PrEP) for HIV, examining its safety and efficacy among pregnant and postpartum women. She also explores STI diagnostics, point-of-care testing, and the prevalence of curable STIs in low- and middle-income countries. Her research seeks to improve access to health interventions, particularly for vulnerable populations like men who have sex with men and transgender women. Dr. Davey’s contributions help shape public health strategies for HIV prevention and sexual health. 🦠💉

Publication Top Notes